ProQR Therapeutics BV (NASDAQ: PRQR) — Perfil da empresa, notícias e dados financeiros
ProQR Therapeutics is a biotech firm advancing RNA therapies for rare genetic diseases from the Netherlands, targeting severe conditions.
ProQR Therapeutics BV
ProQR Therapeutics (NASDAQ:PRQR) is a biotech firm focused on the development of transformative RNA therapies for severe genetic rare diseases. Based out of the Netherlands, ProQR is dedicated to pioneering new ways to treat diseases that have limited or no treatment options. The company's research primarily centers on targeting disorders in the liver and central nervous system, as well as certain eye diseases. Among its notable projects are therapies aimed at addressing conditions like cystic fibrosis and dystrophic epidermolysis bullosa. ProQR’s objective is to leverage its proprietary RNA repair platform technologies to create medicines that can profoundly improve the lives of patients suffering from these debilitating diseases.
Resumo
Operações
Produtos e/ou serviços de ProQR Therapeutics BV
- Axiomer Editing Oligonucleotides technology, a next-generation RNA editing platform aimed at making precise, single nucleotide changes to RNA to correct genetic diseases.
- Sepofarsen, a first-in-class RNA therapy for Leber’s Congenital Amaurosis 10 (LCA10), aiming to restore vision in individuals with this inherited retinal disease.
- QR-421a, an investigational RNA-based therapy targeting Usher syndrome and non-syndromic retinitis pigmentosa, focusing on mutations in the USH2A gene.
- QR-1123, a therapy aimed at treating autosomal dominant retinitis pigmentosa caused by the P23H mutation in the RHO gene, intended to preserve vision.
- QR-504a, a therapy targeting Fuchs Endothelial Corneal Dystrophy (FECD), designed to address the trinucleotide repeat expansion in the TCF4 gene associated with the disease.
- Eluforsen, developed for the treatment of cystic fibrosis, targets the F508del mutation in the CFTR gene to improve lung function and respiratory symptoms.
equipe executiva do ProQR Therapeutics BV
- Daniel Anton de BoerFounder, CEO & Executive Director
- Gerard PlatenburgCo-Founder, Chief Scientific Officer & Executive Director
- Dennis HomChief Financial Officer
- Sheila SponseleeChief People & Operations Officer
- Sarah Cue KielyVice President of Investor Relations & Corporate Communications
- Cristina Lopez LopezChief Medical Officer
- Christopher HartChief Data & AI Officer
- Golnar KarimianHead of Hepatology
- Sandra van der KolkJunior Financial Controller
Últimas notícias sobre a ProQR Therapeutics BV
Principais indicadores financeiros
Resultados divulgados pela ProQR Therapeutics BV, em EUR.
- Cap. de mercado
- 189,1 mi
- Receita (TTM)
- 18,4 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.5
- Dividend yield
- —
- Margem de lucro
- -228.2%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 15,3 mi | -42,2 mi | -40,5 mi | |
| 18,9 mi | -30,5 mi | -27,8 mi | |
| 6,5 mi | -31,9 mi | -28,1 mi | |
| 3,6 mi | -65,2 mi | -64,4 mi |